KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CareDx (CDNA) Gross Profit: 2013-2025

Historic Gross Profit for CareDx (CDNA) over the last 13 years, with Sep 2025 value amounting to $75.6 million.

  • CareDx's Gross Profit rose 19.86% to $75.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $265.2 million, marking a year-over-year increase of 14.24%. This contributed to the annual value of $252.1 million for FY2024, which is 27.96% up from last year.
  • According to the latest figures from Q3 2025, CareDx's Gross Profit is $75.6 million, which was up 21.16% from $62.4 million recorded in Q2 2025.
  • In the past 5 years, CareDx's Gross Profit ranged from a high of $75.6 million in Q3 2025 and a low of $45.6 million during Q4 2023.
  • Over the past 3 years, CareDx's median Gross Profit value was $61.7 million (recorded in 2025), while the average stood at $59.0 million.
  • Its Gross Profit has fluctuated over the past 5 years, first spiked by 103.87% in 2021, then decreased by 22.39% in 2023.
  • Over the past 5 years, CareDx's Gross Profit (Quarterly) stood at $58.4 million in 2021, then increased by 0.55% to $58.7 million in 2022, then decreased by 22.39% to $45.6 million in 2023, then surged by 43.72% to $65.5 million in 2024, then grew by 19.86% to $75.6 million in 2025.
  • Its last three reported values are $75.6 million in Q3 2025, $62.4 million for Q2 2025, and $61.7 million during Q1 2025.